Suppr超能文献

心脏移植中从基于钙调神经磷酸酶抑制剂的每日两次治疗转换为每日一次缓释他克莫司后依从性增加:一项预实验研究。

Increased adherence after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation: a pre-experimental study.

作者信息

Doesch A O, Mueller S, Konstandin M, Celik S, Erbel C, Kristen A, Frankenstein L, Koch A, Dengler T J, Ehlermann P, Zugck C, De Geest S, Katus H A

机构信息

Department of Cardiology, University of Heidelberg, Heidelberg, Germany.

出版信息

Transplant Proc. 2010 Dec;42(10):4238-42. doi: 10.1016/j.transproceed.2010.09.074.

Abstract

BACKGROUND

Modified release tacrolimus (TAC) is a new, once-daily oral formulation of the established immunosuppressive agent TAC. Simplification of regimen has been associated with better adherence. This study evaluated patient adherence, as well as safety and efficacy among chronic stable heart transplantation (HT) patients switched from a conventional twice daily calcineurin inhibitor-based regimen (TAC or cyclosporine A [CsA]) to (once daily) modified release TAC.

METHODS

We switched 54 chronic stable patients (41 males and 13 females) from twice daily dosing with conventional TAC or CsA to once daily dosing with modified release TAC. Self-reported adherence was assessed at baseline and at 4 months after the switch using the Basel Assessment of Adherence with Immunosuppressive Medication Scale [BAASIS]), a 4-item validated questionnaire including also a Visual Analogue Scale (VAS). Nonadherence was defined as any self-reported nonadherence on any item.

RESULTS

Modified release TAC was discontinued in 4 patients because of diarrhea (n = 1) or gastrointestinal discomfort (n = 3) leaving 50 evaluable patients. Overall nonadherence at baseline for any of the 4 items was 74% versus 38% after 4 months (P = .0001). Thereafter, adherence improved in 28 patients (56.0%), was unchanged in 18 (36.0%), and decreased in 4 subjects (8.0%). The VAS score improved from 82.3% ± 2.6% to 97.5% ± 4.8% (P < .0001). No significant changes were observed after 4 months regarding hematologic, renal, or liver function parameters (all P = NS).

CONCLUSIONS

Therapeutic regimens for transplant recipients are often complex, contributing to a high incidence of medication nonadherence. This study in chronic, stable, heart transplantation patients demonstrated a significant improvement in patient adherence after a switch to modified release TAC, which was generally well tolerated.

摘要

背景

他克莫司缓释制剂(TAC)是已确立的免疫抑制剂TAC的一种新型每日一次口服制剂。治疗方案的简化与更好的依从性相关。本研究评估了从传统的基于钙调神经磷酸酶抑制剂的每日两次给药方案(TAC或环孢素A [CsA])转换为(每日一次)他克莫司缓释制剂的慢性稳定心脏移植(HT)患者的依从性、安全性和疗效。

方法

我们将54例慢性稳定患者(41例男性和13例女性)从每日两次服用传统TAC或CsA改为每日一次服用他克莫司缓释制剂。在基线和转换后4个月时,使用巴塞尔免疫抑制药物依从性评估量表[BAASIS])评估自我报告的依从性,这是一份经过验证的4项问卷,还包括一个视觉模拟量表(VAS)。不依从被定义为任何一项自我报告的不依从。

结果

4例患者因腹泻(n = 1)或胃肠道不适(n = 3)停用他克莫司缓释制剂,剩余50例可评估患者。4项中的任何一项在基线时的总体不依从率为74%,4个月后为38%(P = .0001)。此后,28例患者(56.0%)的依从性有所改善,18例(36.0%)保持不变,4例患者(8.0%)下降。VAS评分从82.3% ± 2.6%提高到97.5% ± 4.8%(P < .0001)。4个月后,血液学、肾脏或肝功能参数未观察到显著变化(所有P = 无显著性差异)。

结论

移植受者的治疗方案通常很复杂,导致药物不依从的发生率很高。这项针对慢性、稳定的心脏移植患者的研究表明,转换为他克莫司缓释制剂后患者依从性有显著改善,且总体耐受性良好。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验